[
    [
        {
            "time": "2021-11-26",
            "original_text": "美团Q3收入同比增长37.9%至488.3亿元 同道猎聘Q3净利增长1.26倍",
            "features": {
                "keywords": [
                    "美团",
                    "Q3",
                    "收入",
                    "同比增长",
                    "同道猎聘",
                    "净利增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "互联网",
                    "招聘行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "美团Q3收入同比增长37.9%至488.3亿元 同道猎聘Q3净利增长1.26倍",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "复星医药：撤回申请！抗过敏仿制药，投入已超千万",
            "features": {
                "keywords": [
                    "复星医药",
                    "撤回申请",
                    "抗过敏仿制药",
                    "投入"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：撤回申请！抗过敏仿制药，投入已超千万",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "复星医药：桂林南药通过药品GMP符合性现场检查",
            "features": {
                "keywords": [
                    "复星医药",
                    "桂林南药",
                    "GMP",
                    "符合性检查"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：桂林南药通过药品GMP符合性现场检查",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "复星医药：复星医药产业于中国境内FCN-159片用于I型神经纤维瘤的治疗启动II期临床研究",
            "features": {
                "keywords": [
                    "复星医药",
                    "FCN-159片",
                    "I型神经纤维瘤",
                    "II期临床研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：复星医药产业于中国境内FCN-159片用于I型神经纤维瘤的治疗启动II期临床研究",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "复星医药：子公司用于“原料药(磺胺多辛、乙胺嘧啶、盐酸莫西沙星)、盐酸莫西沙星片”的生产场地通过GMP符合性检查",
            "features": {
                "keywords": [
                    "复星医药",
                    "原料药",
                    "盐酸莫西沙星片",
                    "GMP符合性检查"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：子公司用于“原料药(磺胺多辛、乙胺嘧啶、盐酸莫西沙星)、盐酸莫西沙星片”的生产场地通过GMP符合性检查",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "复星医药：拟参与设立安吉基金和徐州基金",
            "features": {
                "keywords": [
                    "复星医药",
                    "安吉基金",
                    "徐州基金",
                    "设立"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药行业",
                    "投资行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：拟参与设立安吉基金和徐州基金",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-26",
            "original_text": "盟科药业冲刺科创板；阿里健康中期业绩；复星医药双抗在澳获批临试",
            "features": {
                "keywords": [
                    "盟科药业",
                    "科创板",
                    "阿里健康",
                    "中期业绩",
                    "复星医药",
                    "双抗",
                    "澳洲",
                    "临试"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药行业",
                    "科技行业",
                    "健康行业"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "盟科药业冲刺科创板；阿里健康中期业绩；复星医药双抗在澳获批临试",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]